Abstract-Tetrahydrobiopterin is an essential cofactor required for the synthesis of NO. GTP cyclohydrolase I (GTPCH I) is the rate-limiting enzyme for tetrahydrobiopterin production in endothelial cells, yet little is known about the subcellular localization of this enzyme. In this study, we demonstrated that GTPCH I is localized to caveolar membrane microdomains along with caveolin-1 and endothelial NO synthase. GTPCH I activity was detected in isolated caveolar membranes from cultured endothelial cells. Confocal and electron microscopy analyses confirmed GTPCH I colocalization with caveolin-1. Consistent with in vitro studies, GTPCH I activity was evident in isolated caveolar microdomains from lung homogenates of wild-type mice. Importantly, a 2-fold increase in GTPCH I activity was detected in the aortas of caveolin-1-deficient mice, suggesting that caveolin-1 may be involved in the control of GTPCH I enzymatic activity. Indeed, overexpression of caveolin-1 inhibits GTPCH I activity, and tetrahydrobiopterin biosynthesis is activated by the disruption of caveolae structure. These studies demonstrate that GTPCH I is targeted to caveolae microdomains in vascular endothelial cells, and tetrahydrobiopterin production occurs in close proximity to endothelial NO synthase. In addition, our findings provide new insights into the regulation of GTPCH I activity by the caveolar coat protein, caveolin-1. Key Words: GTP-cyclohydrolase I Ⅲ tetrahydrobiopterin Ⅲ endothelium Ⅲ caveolin-1 Ⅲ nitric oxide T he production of the vasodilator NO by endothelial NO synthase (eNOS) is critical for the maintenance of normal vasomotor function. 1 Tetrahydrobiopterin (BH 4 ) is an essential cofactor required for activity of eNOS. 2 We and others have shown that the vascular endothelium is a major source of BH 4 in the arterial wall. 3-5 BH 4 is synthesized from GTP in a 3-step process that is initiated by the enzyme GTP cyclohydrolase I (GTPCH I). 6 The molecular mechanisms regulating GTPCH I activity in the vascular endothelium are not well understood. GTPCH I activity has been demonstrated to be increased by cytokines, hydrogen peroxide, protein kinase C, and fluid shear stress imposed on endothelium by circulating blood. [7] [8] [9] [10] Several groups have also demonstrated that protein-protein interactions can influence GTPCH I activity in vitro. 11, 12 Most notably, the N-terminal sequence of GTPCH I was shown to bind several membraneassociated proteins, suggesting that GTPCH I may be involved in membrane trafficking. 12 It is now established that eNOS activity is regulated at the posttranscriptional level by the protein caveolin-1, an important structural protein associated with plasma membrane microdomains called caveolae. [13] [14] [15] [16] In endothelial cells, caveolae are flask-like shape invaginations of the plasma membrane and associated vesicles that provide a platform for many signaling complexes. 17, 18 The role of caveolin-1 in the control of GTPCH I function and BH 4 synthesis has not been studied in vitro or in vivo. Because proper eNOS function depends on both GTPCH I activity and its subcellular localization to caveolae, 19 we hypothesized that GTPCH I localizes in caveolae and is regulated by caveolin-1.
T he production of the vasodilator NO by endothelial NO synthase (eNOS) is critical for the maintenance of normal vasomotor function. 1 Tetrahydrobiopterin (BH 4 ) is an essential cofactor required for activity of eNOS. 2 We and others have shown that the vascular endothelium is a major source of BH 4 in the arterial wall. [3] [4] [5] is synthesized from GTP in a 3-step process that is initiated by the enzyme GTP cyclohydrolase I (GTPCH I). 6 The molecular mechanisms regulating GTPCH I activity in the vascular endothelium are not well understood. GTPCH I activity has been demonstrated to be increased by cytokines, hydrogen peroxide, protein kinase C, and fluid shear stress imposed on endothelium by circulating blood. [7] [8] [9] [10] Several groups have also demonstrated that protein-protein interactions can influence GTPCH I activity in vitro. 11, 12 Most notably, the N-terminal sequence of GTPCH I was shown to bind several membraneassociated proteins, suggesting that GTPCH I may be involved in membrane trafficking. 12 It is now established that eNOS activity is regulated at the posttranscriptional level by the protein caveolin-1, an important structural protein associated with plasma membrane microdomains called caveolae. [13] [14] [15] [16] In endothelial cells, caveolae are flask-like shape invaginations of the plasma membrane and associated vesicles that provide a platform for many signaling complexes. 17, 18 The role of caveolin-1 in the control of GTPCH I function and BH 4 synthesis has not been studied in vitro or in vivo. Because proper eNOS function depends on both GTPCH I activity and its subcellular localization to caveolae, 19 we hypothesized that GTPCH I localizes in caveolae and is regulated by caveolin-1.
Materials and Methods

Experimental Animals
Male caveolin-1-deficient mice (Cav1 tm1Mls /J; Cav1 Ϫ/Ϫ ) and eNOS-deficient mice (B6.129P2-Nos3 tm1Unc /J; eNOS Ϫ/Ϫ ), as well as strain-matched wild-type mice B6129SF2/J and C57BL/6J, respectively, were obtained from the Jackson Laboratories (Bar Harbor, ME). Lungs of GTPCH I-transgenic mice were provided by Dr Alex Chen (Michigan State University, East Lansing, Mich) with permission of Dr Keith M. Channon (University of Oxford, Oxford, United Kingdom). Mice were maintained on standard chow with free access to drinking water. Housing facilities and all of the experimental protocols were approved by the Mayo Clinic Institutional Animal Care and Use Committee and complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were euthanized by overdose of pentobarbital (60 mg/kg IP), and whole aortas and lungs were carefully harvested and dissected free from connective tissue.
Cell Culture and Adenoviral Overexpression Techniques
Human umbilical vein endothelial cells (HUVECs) were obtained from Cambrex and were passaged in endothelial growth medium-2 (Cambrex). All of the experiments were performed using HUVECs between passages 3 and 7. A recombinant adenovirus encoding the human GTPCH I gene (Ad-GTPCH I) driven by a cytomegalovirus promoter 20 at a multiplicity of infection (MOI) of 100 was used to overexpress GTPCH I to a level that was detectable by Western blot analysis. In separate studies, adenoviral encoding human caveolin-1 (Ad-Cav1; Vector Biolabs) at an MOI of 30 was used to overexpress caveolin-1. HUVECs were infected for 12 hours in serum-free medium (EBM-2) and were then fed with growth medium for 48 hours before analysis. A recombinant adenoviral vector with a deletion of ⌬E1 (Ad-⌬E1) was used as a control.
Western Blot Analysis
Cells were washed twice in cold PBS and flash frozen in 200 L of lysis buffer 10 in an ethanol/dry ice bath followed by scraping and a 5-second sonication to achieve a homogeneous solution. Twenty to 30 g of total protein were separated by 12% SDS-PAGE, transferred to nitrocellulose membrane, and stained with Ponceau-S stain (Sigma) to ensure equal protein loading. For Western blot analysis, membranes were probed using primary antibodies against anticaveolin-1, anti-eNOS (BD Biosciences), or anti-GTPCH I. 4 Membranes were then incubated for 1 hour with horseradish peroxidase-conjugated anti-IgG antibodies and visualized using enhanced chemiluminescence detection (Amersham).
Isolation of Triton X-100 Soluble and Insoluble Fractions
HUVECs were grown in 10-cm dishes until 70% confluent. Cells were harvested in lysis buffer containing 1% Triton X-100 and sonicated for 5 seconds. Cell lysates were then centrifuged at 100 000g for 1 hour, and the supernatant was collected (soluble fraction). The resulting pellet was washed twice with lysis buffer, resuspended in 100 L of lysis buffer, and sonicated for 30 seconds to achieve a homogeneous solution (insoluble fraction).
Isolation of Caveolae-Enriched Membranes
For each experiment, pooled Ad-GTPCH I-transduced HUVECs from 6 dishes or whole mouse lung was homogenized in cold buffer A (0.25 mol/L of sucrose, 1 mmol/L of EDTA, and 20 mmol/L of Tricine [pH 7.8] ) and centrifuged at 1000g for 10 minutes. The supernatant was saved and layered onto 30% Percoll (Sigma) and centrifuged at 84 000g for 30 minutes. The membrane fraction (visualized by an opaque band) was collected and brought to a volume of 2 mL with buffer A and sonicated 3 times for 30 seconds, and protein content was determined. Equal amounts of protein from each group were then resuspended in a 23% solution of Optiprep (Accurate Chemical) and placed in a centrifuge tube. A 20% to 10% Optiprep gradient was layered on top and centrifuged at 52 000g for 90 minutes. Density gradient fractions were collected in 1.5-mL aliquots from top to bottom with the first 4 fractions containing the low buoyant density membrane fractions that were enriched in caveolae-associated proteins.
Immunofluorescent Imaging
HUVECs were plated onto tissue culture chamber slides and infected with an adenovirus encoding hemagglutinin-tagged GTPCH I (a gift from Dr Keith Channon) 21 at an MOI of 20 in EBM-2 for 6 hours. Cells were then fed growth medium for 24 hours before analysis. After treatment, cells were fixed with methanol for 15 minutes at 4°C and blocked with 10% normal goat serum for 30 minutes. Slides were then incubated for 1 hour with a mixture of mouse anticaveolin-1 and rabbit anti-hemagglutinin antibody (Sigma). A secondary antibody mixture of goat antimouse fluorescein isothiocyanate and goat antirabbit Texas Red (Invitrogen) was added and incubated for 45 minutes. Cells were then incubated for 5 minutes with 10 g/mL of Hoechst 33258 (Sigma) to stain for nuclei. Cover slips were mounted using Prolong Gold mounting medium (Invitrogen), and the cells were visualized using a Zeiss LSM 510 laser scanning confocal microscope.
Immunogold Labeling of Mouse Aorta by Electron Microscopy
Isolated aortic ring segments from wild-type mice were fixed in 4% formaldehyde plus 1% glutaraldehyde overnight, dehydrated in a series of ethanol from 35% to absolute while progressively lowering the temperature to Ϫ20°C, embedded in LR white resin, and polymerized at 55°C. Thin sections were mounted on nickel grids and labeled for GTPCH I and double-labeled for caveolin-1. GTPCH I was labeled by blocking free aldehydes with 1% glycine and blocking with PBS containing Tween-20 and 2% normal goat serum. A rabbit polyclonal antibody specific for mouse GTPCH I 4 was diluted 1:2 in PBS containing Tween-20 and 2% normal goat serum, and grids were incubated at room temperature for 2 hours. Grids were rinsed extensively in PBS containing Tween-20 and incubated in a goat antirabbit secondary antibody conjugated to 10-nm gold beads (Amersham) for 1 hour at room temperature. Caveolin-1 was labeled by blocking in glycine and PBS containing Tween-20 and 2% normal goat serum similar to GTPCH I labeling. Mouse anticaveolin-1 was diluted 1:5 in PBS containing Tween-20 and 2% normal goat serum and incubated for 2 hours at room temperature. After rinsing in PBS containing Tween-20, the sections were incubated in goat antimouse secondary antibody conjugated to 5-nm gold beads (Amersham). When double labeling was completed, the sections were stained in lead and uranyl for transmission electron microscopy.
Measurements of Biopterin Levels and GTP-Cyclohydrolase I Activity
BH 4 and 7,8-dihydrobiopterin levels, as well as GTPCH I enzymatic activity, were determined in fresh aortas using a reverse-phase high-performance liquid chromatography method, as described previously. 4, 22 
Statistical Analysis
Data are expressed as meansϮSEMs, and "n" indicates the number of animals from which tissues were harvested. Single values were compared by 1-way ANOVA with Bonferroni correction for multiple comparisons. For simple comparisons between 2 groups, an unpaired Student t test was used where appropriate. A value of PϽ0.05 was considered significant.
Results
In Vitro Analysis of GTPCH I Subcellular Localization
To track GTPCH I protein localization in vitro, an adenoviral construct encoding human GTPCH I was used in HUVECs at an MOI of 100 ( Figure 1A) . Initial experiments demonstrated that GTPCH I protein expression was equally partitioned to both Triton X-100 soluble and Triton X-100 insoluble fractions, suggesting that a significant fraction of GTPCH I protein is associated with cellular membranes, along with caveolin-1 and eNOS ( Figure 1A ). Subsequent studies using sucrose gradient ultracentrifugation demonstrated that both GTPCH I protein expression and activity were localized to caveolar microdomains, as well as noncaveolar-associated membrane fractions ( Figure 1B) . Confocal microscopic analysis of HUVECs infected with an adenovirus encoding a hemagglutinin-tagged GTPCH I demonstrated that GTPCH I staining was localized to perinuclear regions of the cell ( Figure 1C ) as reported previously 21 ; however, there was also a considerable amount of colocalization of GTPCH I with caveolin-1 at the cell membrane ( Figure 1C ).
In Vivo Analysis of GTPCH I Subcellular Localization
To determine whether similar results could be obtained in vivo, initial studies using electron microscopy were performed to determine whether GTPCH I and caveolin-1 might be localized in similar subcellular compartments to each other in endothelial cells from wild-type mouse aorta. Indeed, a substantial amount of GTPCH I labeling was found both in the cytoplasm and at the plasma membrane of mouse aortic endothelial cells. Dual labeling for both caveolin-1 and GTPCH I showed that the 2 proteins were often associated in close proximity with each other (Figure 2A ). Analysis of membrane-associated proteins using detergent-free sucrose density gradient ultracentrifugation demonstrated that GT-PCH I activity is concentrated in the caveolae-rich fraction of the wild-type mouse lung ( Figure 2B ).
To further investigate the functional significance of GT-PCH I localization to caveolar microdomains, we measured GTPCH I protein expression and activity in the aortas of Cav1 Ϫ/Ϫ mice, which lack any morphological caveolar structures. 23 Western blot analysis demonstrated similar levels of GTPCH I protein expression in the aorta from wild-type and Cav1 Ϫ/Ϫ mice ( Figure 3A) , whereas high-performance liquid chromatography analysis revealed a significant increase in GTPCH I activity in the aorta and lung from Cav1 Ϫ/Ϫ mice when compared with wild-type controls ( Figure 3B ). In contrast, GTPCH I activity was unaltered in other organs, such as the brain and liver of Cav1 Ϫ/Ϫ mice (Table) . Along with the increases in GTPCH I activity, we also observed an increase in BH 4 levels from the aorta of Cav1 Ϫ/Ϫ mice compared with wild-type controls, whereas oxidative products of BH 4 and 7,8-dihydrobiopterin levels were unchanged (data not shown), indicating that the selective increase in BH 4 levels was because of the increased de novo biosynthesis of BH 4 via GTPCH I ( Figure 3C ). Furthermore, we could not detect a difference in BH 4 levels in the aortas of eNOS Ϫ/Ϫ mice ( Figure 3D ). Together, these data demonstrate that caveolin-1 may act as a functional inhibitor of GTPCH I activity in vivo.
Interaction Between Caveolin-1 and GTPCH I Activity
Ad-Cav1-transduced cells showed increased Cav1 protein expression, as detected by Western blot analysis ( Figure 4A ). Interestingly, enzymatic activity of GTPCH I was reduced by Ϸ50% in HUVECs transduced with Ad-Cav1 as compared with the control Ad-⌬E1 vector ( Figure 4B ). Western blot analysis of membrane fractions of the wildtype mouse lung demonstrated that GTPCH I was present in the caveolae-rich fraction (fraction 2; Figure 5A , top), again confirming that GTPCH I is targeted to the cholesterol-rich, low buoyant density caveolae-rich fraction of the membrane. In contrast, GTPCH I was significantly reduced in fraction 2 of Cav1 Ϫ/Ϫ mice ( Figure 5A , bottom). To further demonstrate that GTPCH I activity is localized in cholesterol-enriched membrane microdomains, isolated mouse aortas were treated in vitro with methyl-␤-cyclodextrin (␤-CD) that binds cholesterol and cause reversible disassembly of caveolae. Indeed, treatment with ␤-CD significantly increased BH 4 levels in wild-type but not in Cav1 Ϫ/Ϫ mice ( Figure 5B ).
Caveolar Activity of GTPCH I in GTPCH I Transgenic Mice
Because overexpression of GTPCH I in endothelium has well-established vascular protective effects, we performed experiments on transgenic mice with endothelial-targeted overexpression of GTPCH I. Consistent with findings on cultured endothelial cells, we found that GTPCH I activity was significantly increased in caveolae-rich fractions (and noncaveolae membrane fractions) of GTPCH I transgenic mice as compared with wild-type mice ( Figure 6 ).
Discussion
The results of this study reveal several novel findings regarding the regulation of BH 4 synthesis in endothelial cells. First, we demonstrate that GTPCH I protein expression and enzymatic activity are localized in both caveolar and noncaveolar membrane compartments. Second, enzymatic activity of GTPCH I and BH 4 levels were increased in the aorta of Cav1 Ϫ/Ϫ mice. Third, caveolin-1 overexpression inhibits GTPCH I activity, and BH 4 biosynthesis is activated by the disruption of caveolae structure. Fourth, overexpression of GTPCH I increased GTPCH I activity in caveolar microdomains of endothelial cells. Given that optimal NO synthesis occurs in caveolar microdomains, we propose that the close spatial localization of eNOS and GTPCH I may help to ensure proper NO synthesis in endothelial cells. In addition, it is likely that caveolar localization contributes to the well-established vascular protective effect of GT-PCH I in experimental models of diabetes mellitus and hypercholesterolemia, as well as in pulmonary and systemic hypertension. 24 Although GTPCH I is known to be critical for the synthesis of BH 4 in multiple cell types, there is little information about the subcellular localization of this enzyme in endothelial cells. Using an adenoviral construct to overexpress human GTPCH I in endothelial cells, we were able to demonstrate that GTPCH I can be equally partitioned into both Triton X-100 soluble and Triton X-100 insoluble fractions. It is unclear at this time what the differences are between these 2 distinct subpopulations of GTPCH I; however, it is possible that there are posttranslational modifications to GTPCH I that may affect its solubility in Triton X-100. Further investigation of the membrane-associated pool of GTPCH I using sucrose gradient ultracentrifugation revealed that GTPCH I can be targeted to low buoyant density membrane fractions called caveolae and other membrane domains, such as Golgi, endoplasmic reticulum, and clatherin-coated pits, along with eNOS and caveolin-1. Confocal microscopic analysis confirmed that GTPCH I was partially colocalized with caveolin-1 under basal conditions in vitro. However, confocal microscopy also revealed GTPCH I in membrane patches and in cytosol that did not contain caveolin-1. Based on these studies, GTPCH I localization in caveolae represents only a portion of the GTPCH I pool within the cell. Furthermore, we observed a loss of GTPCH I from caveolar and noncaveolar membranes in Cav1 Ϫ/Ϫ mice, whereas Western blot analysis did not show any change in GTPCH I expression between aortas obtained from wild-type and Cav1
Ϫ/Ϫ mice. These observations are consistent with our conclusion regarding the caveolar localization of GTPCH I. Whether trafficking 28 of GTPCH I or BH 4 biosynthesis occurs in caveolae remains to be determined in future studies.
Because caveolin-1 has been reported to be an important regulator of eNOS activity 29 and eNOS activity is enhanced in Cav1
Ϫ/Ϫ mice, 23, 30 we determined basal GTPCH I activity in the aortas of Cav1 Ϫ/Ϫ mice. Surprisingly, we found that there was a 2-fold increase in GTPCH I activity in aortas of Cav1 Ϫ/Ϫ mice when compared with wild-type mice. We also observed a selective increase in BH 4 levels from the aorta of Cav1 Ϫ/Ϫ mice, suggesting that this increase was caused by the increased de novo biosynthesis of BH 4 via GTPCH I. In contrast, GTPCH I activity was unchanged in the liver or brain of Cav1 Ϫ/Ϫ mice when compared with wild-type controls, suggesting that caveolin-1 may exert an inhibitory effect on basal GTPCH I activity in vivo, in an organ-specific manner. Alternatively, this observation could also be explained by differential regulation of BH 4 biosynthesis between large conduit and small resistance arteries. Indeed, it is generally accepted that NO (and possibly BH 4 ) plays more prominent functional role in the control of large conduit arteries. 31 The inhibitory effect of caveolin-1 on GTPCH I activity was further demonstrated by the fact that transduction of HUVECs with Ad-Cav1 resulted in significant suppression of GTPCH I activity. On the other hand, treatment with the cholesterol-binding drug ␤-CD, which prevents formation of functional caveolae by depletion of cholesterol, 32 increased BH 4 biosynthesis in the aorta of wild-type mice. Of note, ␤-CD treatment did not further increase BH 4 levels in the aorta of Cav1 Ϫ/Ϫ mice, reinforcing our conclusion that caveolin-1 has a negative regulatory effect on the enzymatic activity of GTPCH I.
Over the past decade, studies from several groups have reported the beneficial effects of increasing endothelial BH 4 levels in various models of vascular disease. Indeed, a number of investigations have demonstrated that supplementation with BH 4 can prevent endothelial dysfunction. Accordingly, acute and chronic supplementation of BH 4 in experimental models of oxidative stress and in patients with cardiovascular disease improved endothelium-dependent relaxations and increased eNOS activity. 5, [33] [34] [35] [36] In the present Ϫ/Ϫ mice were performed that separate caveolar microdomains from other cellular constituents. Western blot analysis with anti-GTPCH I antibody was performed to determine the localization of GTPCH I in gradient fractions. Please note that GTPCH I was fractionated to the low buoyant density fraction in wild-type mice (top), and this was almost eliminated in fraction 2 of Cav1 Ϫ/Ϫ mice (bottom). B, Effect of cholesterol depletion on BH 4 levels. Isolated mouse aortas of wild-type (WT; B6129SF2/J) and Cav1 Ϫ/Ϫ mice were exposed in vitro with ␤-CD (10 mmol/L) for 1 hour at 37°C, and BH 4 levels were then determined. Bar graph showing BH 4 levels after treatment without or with ␤-CD. Results are meansϮSEMs (nϭ6). *PϽ0.05 vs untreated wild-type mice. study, GTPCH I enzymatic activity was increased in the low buoyant density membrane fraction of transgenic mice with endothelial-targeted overexpression of GTPCH I. This observation is important, because several recent studies demonstrated that endothelial overexpression of GTPCH I reduces superoxide anion production and preserves NO release, suggesting that endothelial dysfunction can be restored by increasing the local concentration of BH 4 . 24, 25, 27 Relevant to interpretation of our results, previous studies have demonstrated that caveolar microdomains are sensitive to oxidative and nitrosative stress. 37, 38 Whether GTPCH I localization in the caveolar membrane is critical for the protection of caveolae against oxidative stress in vivo remains to be determined.
Perspectives
Results of the present study have several important implications for the understanding of vascular endothelial function. In addition to the well-established role of BH 4 in the activity of eNOS, our findings underscore the importance of cellular localization of GTPCH I, a critical enzyme responsible for the biosynthesis of BH 4 . Colocalization of GTPCH I and eNOS in caveolae is most likely designed to provide the optimal local concentration of BH 4 required for the biosynthesis of endothelial NO. Because elevated concentration of superoxide anion and subsequent formation of peroxynitrite are some of the most important mechanisms underlying endothelial dysfunction, the relevance of BH 4 in the preservation of caveolar architecture and function should be investigated in the future studies.
